Protective effects of MK-801 on manganese-induced glutamate metabolism disorder in rat striatum.
Manganese (Mn) is one of the ubiquitous environmental pollutants that can induce an indirect excitotoxicity caused by altered glutamate (Glu) metabolism. The present study has been carried out to investigate the mechanisms of Glu metabolism disorder and the neuroprotective role of MK-801, a non-competitive N-methyl-D-aspartate receptor antagonist, against Mn-induced excitotoxicity in rat striatum. Fifty rats were randomly divided into five groups with 10 animals in each group: control group, Mn-treated group (8, 40, and 200micromol/kg), and MK-801-pre-treated group. Administration of MnCl(2) x 6H(2)O at dose of 200micromol/kg body weight for 4 weeks significantly increased the concentrations of Glu and Mn in the striatum (P<0.01). In addition, Mn also increased the activity of phosphate-activated glutaminase (PAG) (54.38%, P<0.01), enhanced striatum cell apoptosis rate (65.04%, P<0.01) and decreased the activity of glutamine synthetase (GS) (28.88%, P<0.01). Pre-treatment with MK-801 at a dose of 0.3micromol/kg body weight for 4 weeks prior to 200micromol/kg Mn administration prevents the alterations of the activities of PAG and GS and concentrations of glutamine (Gln). In addition, pre-treatment with MK-801 significantly reduced the striatum cell apoptosis rate. In conclusion, the results suggest that MK-801 possesses the ability to attenuate Mn-induced Glu metabolism disorder in the striatum through mechanisms involving disruption enzyme activities of GS and PAG.
Xu
Bin
B
Department of Environmental Health, School of Public Health, China Medical University, Shenyang, Liaoning, People's Republic of China.
Xu
Zhao-Fa
ZF
Deng
Yu
Y
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism / Q000648:ultrastructure; D016291:Dizocilpine Maleate / Q000008:administration & dosage / Q000627:therapeutic use*; D004785:Environmental Pollutants / Q000493:pharmacokinetics / Q000633:toxicity*; D005260:Female; D005974:Glutamate-Ammonia Ligase / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism*; D005972:Glutaminase / Q000378:metabolism; D008297:Male; D008345:Manganese / Q000493:pharmacokinetics / Q000633:toxicity*; D046529:Microscopy, Electron, Transmission; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D020258:Neurotoxicity Syndromes / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors
D004785:Environmental Pollutants; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D008345:Manganese; D016291:Dizocilpine Maleate; D005972:Glutaminase; D005974:Glutamate-Ammonia Ligase